SCHEMBL1924537

SCHEMBL1924537

Cc1cc(-c2cc(C(F)(F)F)n3cnc(-c4cccnc4)c3n2)ccc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.43
▸ PSD A5PKW4 5/20 0.42
▸ TP53 P04637 1/20 0.39
▸ MAPT P10636 1/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.37
▸ BRAF P15056 1/20 0.36
▸ MAPK14 Q16539 1/20 0.36
▸ CYP2A6 P11509 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ PTGS1 P23219 1/20 0.34
▸ PTGS2 P35354 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1925499 0.89 TP53 (0.43) GAAPSDTP53MAPTSMN1; SMN2
SCHEMBL1924385 0.88 TP53 (0.35) PSDTP53MAPTNPC1RAB9A
SCHEMBL1924986 0.87 TP53 (0.46) GAAPSDTP53MAPTSMN1; SMN2
SCHEMBL1925737 0.87 PSD (0.42) GAAPSDSMN1; SMN2NPC1RAB9A
SCHEMBL1924686 0.87 PSD (0.50) GAAPSDTP53MAPTSMN1; SMN2
SCHEMBL1924659 0.84 GRM2 (0.44) TP53
SCHEMBL1924312 0.83 NPY5R (0.43) PSDMAPTSMN1; SMN2NPC1RAB9A
SCHEMBL1925115 0.83 PIM1 (0.47) SMN1; SMN2NPC1RAB9ARXFP1KDM4E
SCHEMBL1924866 0.81 NPC1 (0.38) GAAPSDSMN1; SMN2NPC1RAB9A
SCHEMBL1924528 0.79 MAPT (0.60) GAAPSDMAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1670801-B1 PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-06-08 — — EP disclosed
US-7514443-B2 Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of metabotropic glutamate receptors HOFFMANN-LA ROCHE INC. (US) 2009-04-07 — — US disclosed
US-20080051421-A1 Pyrazolo-pyridine WICHMANN JUERGEN 2008-02-28 — — US disclosed
US-7329662-B2 Pyrazolo-pyridine HOFFMANN-LA ROCHE INC. (US) 2008-02-12 — — US disclosed
US-20050130992-A1 Pyrazolo-pyridine F. HOFFMANN-LA ROCHE AG (CH) 2005-06-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130992-A1 Pyrazolo-pyridine CHRM2, CHRM1, QDPR GAA 2600/4885PSD 332/4885TP53 3056/4885
US-20080051421-A1 Pyrazolo-pyridine CHRM2, CHRM1, QDPR GAA 2600/4885PSD 332/4885TP53 3056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback